Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Chordoma × nilotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 93 Leukemia, Myeloid, Chronic-Phase 25 Leukemia 21 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Gastrointestinal Stromal Tumors 15 Blast Crisis 9 Neoplasms 8 Neoplasm Metastasis 6 Philadelphia Chromosome 4 Myeloproliferative Disorders 4 Melanoma 4 Leukemia, Myeloid 4 Bone Marrow Diseases 4 Recurrence 3 Leukemia, Myeloid, Acute 3 Leukemia, Myeloid, Accelerated Phase 3 Hematologic Diseases 3 Bronchiolitis Obliterans Syndrome 3 Synovitis, Pigmented Villonodular 2 Ovarian Neoplasms 2 Neoplasm, Residual 2 Hematologic Neoplasms 2 Colorectal Neoplasms 2 Substance Withdrawal Syndrome 1 Sarcoma 1 Retroperitoneal liposarcoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Piebaldism 1 Peritoneal Neoplasms 1 Neurofibromatoses 1

Interventions

Nivolumab 6 Imatinib Mesylate 4 Ipilimumab 3 Cetuximab 3 pembrolizumab 2 palbociclib 2 Specimen Handling 2 Radiotherapy 2 Radiosurgery 2 Protons 2 Proton Therapy 2 Pemetrexed 2 Magnetic Resonance Spectroscopy 2 Cyclophosphamide 2 tazemetostat 1 spartalizumab 1 relatlimab 1 nilotinib 1 camrelizumab 1 avelumab 1 atezolizumab 1 apatinib 1 Zoledronic Acid 1 X-Rays 1 Tiragolumab 1 Thiotepa 1 Surveys and Questionnaires 1 Radiotherapy, Intensity-Modulated 1 Radiation 1 Photochemotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01407198 2025-12-19

Nilotinib With Radiation for High Risk Chordoma

Massachusetts General Hospital

Phase 1 Completed

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡